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Background: Disparities in the prevalence of HIV persist in the southern United States, and young African American
women have a disproportionate burden of HIV as compared with young women of other racial/ethnic
backgrounds. As a result, engaging young African American women in the HIV care continuum through HIV testing
is imperative. This study is designed to reach this key population at risk for HIV. The study seeks to test the efficacy
of two formats of a gender-focused, evidence-based, HIV-risk reduction intervention—the Young Women’s CoOp
(YWC)—relative to HIV counseling and testing (HCT) among young African American women between the ages of
18 and 25 who use substances and have not recently been tested for HIV.
Methods: Using a seek-and-test framework, this three-arm cross-over randomized trial is being conducted in three
county health departments in North Carolina. Each county is assigned to one of three study arms in each cycle: in-
person (face-to-face) YWC, mobile Health (mHealth) YWC, or HCT. At study enrollment, participants complete a risk
behavior survey via audio computer-assisted self-interview, and drug, alcohol, and pregnancy screening tests, and
are then referred to HIV, gonorrhea, and chlamydia testing through their respective health departments. Participants
in either of the YWC arms are asked to return approximately 1 week later to either begin the first of two in-person
individual intervention sessions or to pick up the mHealth intervention preloaded on a tablet after a brief
introduction to using the app. Participants in all arms are asked to return for a 6-month follow-up and 12-month
follow-up, and repeat the survey and biological testing from baseline.
Discussion: The findings from this study will demonstrate which delivery format (mHealth or face-to-face) is
efficacious in reducing substance use and sexual risk behaviors. If found to be efficacious, the intervention has
potential for wider dissemination and reach.
Trial registration: ClinicalTrials.gov: NCT02965014. Registered November 16, 2016.
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HIV continues to be a significant public health issue in the
United States. Disparities in the burden of HIV persist with
regard to ethnicity, geographic area, age, and gender. Al-
though African Americans account for 12% of the U.S.
population, they are disproportionately affected by HIV [1].
Furthermore, 57% of African Americans living with HIV
reside in the southern United States [2, 3], and many are
emerging adults. Unfortunately, HIV incidence among
young African American women is also striking. For ex-
ample, African American women aged 20–24 are diagnosed
with HIV at almost 12 times the rate of their White coun-
terparts. In North Carolina, young African American
women are the most affected group of young women; of
the newly diagnosed cases of HIV among young women in
2016, approximately 61% were among African American
young women compared with 36% among White young
women [4]. These statistics illustrate the gravity and need
for interventions to reach young African American women
for increased HIV testing and more gender-focused
prevention.
Engaging young African American women in HIV testing
is essential to improving the health of those who are HIV
positive and reducing the risk of transmission to others.
Only 45% of African American women reported being
tested for HIV in the past year [5]; however, African Ameri-
can women who engage in heterosexual sex account for
about 21% of undiagnosed HIV infections [6]. Conse-
quently, many young African American women may be un-
aware of their HIV-positive status and unknowingly
transmit HIV to others. Many young women know it is im-
portant to get tested, but they face barriers to testing. Some
women may not believe they are at risk for HIV and, as
such, do not get tested [7]. Stigma and shame may also in-
fluence their decision to get tested [8]. In a study of African
American college students in the South, participants cited
that barriers to getting tested were lack of knowledge of
testing sites, a fear of harming a relationship, and a fear of
breaches of confidentiality [9].
The disproportionate burden of HIV among young Af-
rican American women is largely attributable to high
community-level HIV prevalence coupled with con-
densed sexual networks that increase the risk of infec-
tion [10–12]. Given the increased risk of HIV, it is
imperative for young African American women to pro-
tect themselves during sex. Condom use is the most ac-
cessible and inexpensive means of HIV protection to
date. However, only 21% of African American women
used a condom every time they had sex with their part-
ners in the past year [13], indicating that a significant
proportion of women are potentially at risk for HIV.
Several factors have been associated with condomless sex
among young African American women. Gender-based
violence (GBV) and substance use are associated withsexual risk behavior [14–17]. During their lifetime, about
36% of African American women have experienced
sexual violence and 45% of African American women
have experienced intimate partner violence (IPV), in-
cluding sexual and physical violence, and/or stalking
by an intimate partner [18]. IPV often creates power
inequalities among heterosexual couples—women may
not feel empowered to negotiate condom use out of
fear for their safety or resistance from their part-
ners—leading to inconsistent condom use [15, 19–22].
Furthermore, African American women may feel that
asking their partner(s) to use a condom may imply
infidelity [20], or that condoms are unnecessary because
they believe they are in an exclusive relationship [23]. In-
consistent condom use is also associated with substance
use, because young women who drink alcohol or smoke
marijuana are less likely to engage in condom use [14, 16].
More than half (52%) of African American young adults
have engaged in illicit drug use, and in a population of stu-
dents at a historically black college or university (HBCU),
38% and 34% of female students reported binge drinking
and marijuana use, respectively [24, 25]. Much like GBV,
alcohol or other drug (AOD) use may diminish a woman’s
power when engaging in sexual encounters with male
partners. Consequently, it is imperative for HIV preven-
tion interventions to address not only sexual risk behav-
iors but also substance use and violence, and help to
promote women’s empowerment [26].
The original Women’s CoOp (WC) is an HIV behav-
ioral risk-reduction intervention that is gender-focused
and based in empowerment theory and African Ameri-
can feminism [27]. The WC was developed for African
American women who used crack cocaine and tested
during a randomized controlled trial in North Carolina.
The findings indicated that the women in the intervention
arm significantly reduced condomless sex at 6-month
follow-up, and had reductions in homelessness and
increases in employment at 3-month follow-up, compared
with the control and standard-HIV intervention (4-session
HIV counseling and health education intervention with
HIV testing) group arms [27]. Additionally, women in all
groups significantly reduced crack use and sex trading at
follow-up. The WC was classified as a best evidence inter-
vention by the Centers for Disease Control and Prevention
(CDC) [28], and has been adapted for other populations
who use AOD in North Carolina and other settings in the
US and internationally [29]. The most recent WC adapta-
tion, the Young Women’s CoOp (YWC), seeks to reduce
sexual risk behaviors, AOD use, and violence among
young African American women [30, 31]. Among young
women aged 16–19 who had dropped out of school
or considered dropping out of school, the YWC dem-
onstrated efficacy in reducing condomless sex, and
participants in the YWC also had reductions in other
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from partners [31]. Of the approximately one-third of
participants who opted to test for gonorrhea or chla-
mydia, 28% tested positive.
Since its inception, the WC and its adaptations have been
administered in-person by trained interventionists [29];
however, the advent of mobile health (mHealth) technolo-
gies—the delivery of medical and public health information
and services through mobile devices—is an innovative ap-
proach to HIV prevention that has been used among popu-
lations such as female California youth and female African
American emerging adults to address barriers to HIV pre-
vention strategies such as condom use and HIV testing
[32, 33]. Nevertheless, the literature does not widely ad-
dress HIV prevention mHealth interventions geared to-
ward sexual risk and HIV testing together with the nexus
of substance use and victimization that contribute to HIV
risk among young African American women. Given the
significant role of AOD use and violence in influencing
sexual behavior, creating an mHealth intervention that is
woman-focused and addresses the intersections of AOD
use, sexual risk, and violence may be essential to alleviat-
ing the disparities that persist with HIV.
Methods
Aims and objectives
This study seeks to determine the efficacy of a behavioral
health intervention, the YWC delivered in two formats,
relative to standard HIV counseling and testing (HCT) in
reducing risk behaviors such as condomless sex and sub-
stance use. More specifically, this study has four aims, as
follows: (1) Conduct formative research activities to de-
velop a new, age-appropriate WC intervention (YWC),
develop strategies to reach young African American
women who use AOD, and develop the YWC interactive
mHealth application; (2) test the efficacy of the YWC de-
livered face-to-face or via mHealth app, relative to HCT;
(3) estimate the total costs of delivering the face-to-face
YWC and mHealth YWC; and (4) examine participant
and health clinic staff perceptions of the face-to-face YWC
and mHealth YWC. Below, we discuss the study design,
methods, and ethical considerations for the second aim, a
randomized trial.
Study design
This study utilizes a randomized three-group, crossover de-
sign with two intervention arms and one control arm
(shown in Fig. 1). Each county was first randomized to one
of three conditions: face-to-face YWC (intervention),
mHealth YWC (intervention), or HCT (control)—Cycle 1.
Then, controlling for the previous condition, counties were
randomized again to determine their study arm for Cycle 2.
For Cycle 3, counties will be assigned the remaining study
arm. Randomization was conducted via SAS software. Weconsidered each county as a cluster to limit contamination
between study conditions, and used a crossover design to
account for county differences. This crossover design re-
sults in all counties receiving each study arm at some point.
Cycle 1 (with the original randomization) occurred from
January 2017 to January 2018; Cycle 2 (the first crossover)
began in January 2018 and is anticipated to end in October
2018; and Cycle 3 (the second crossover) is anticipated to
occur from October 2018 until July 2019.
Study setting
In collaboration with county health departments, the
Durham County Department of Health, Guilford County
Department of Public Health, and Wake County Human
Services serve as study sites for the randomized trial. In
addition, outreach and recruitment activities are occur-
ring in multiple locations across Durham, Guilford, and
Wake Counties. These counties and health departments
were chosen because of the high rates of HIV and sexu-
ally transmitted infections (STIs) within these counties
and for their relative proximity to each other.
Eligibility criteria
To be eligible for this trial, individuals must meet the fol-
lowing criteria: (1) be age 18–25; (2) self-identify as Black
and/or African American; (3) self-identify as female; (4)
have had penetrative sex with a male partner without
using a condom within the past 3 months; (5) have used
AOD in a greater quantity or for a longer period than they
originally intended within the past 30 days; (6) have not
tested for HIV within the past 3 months; (7) currently res-
ide in Durham, Wake, or Guilford County for at least the
past 6 months; (8) have no intent to move from the area
within the next year; (9) have not participated in the previ-
ous YWC/Teen CoOp randomized controlled trial or the
formative phase of this study; (10) be willing to test for
HIV, chlamydia, and gonorrhea through their respective
county health departments and sign a release; and (11) be
willing to provide locator information for future contact.
During the baseline (i.e., intake) assessment visit,
trained project staff first obtain written consent from the
potential participant. After the participant signs the con-
sent form, detailed contact information is collected to
contact participants for subsequent appointments. Next,
participants complete an adapted version of a risk be-
havior questionnaire (Revised Risk Behavior Assessment)
[34] via audio computer-assisted self-interview software,
regarding the participant’s AOD use, sexual risk and sex-
ual activity, experiences of victimization and violence,
gender roles, communication, and current health status.
Participants undergo biological testing for pregnancy
and drug use and complete an alcohol breath scan. In
addition, participants are referred to the health department
for HIV and STI (chlamydia and gonorrhea) testing. These
Randomize Counties
Standard of Care
HCT
Outreach/In-Reach
Eligibility screen in community/
clinics
Baseline Visit
Survey, Biological*, Referral to
HD for HIV/STI Testing
12-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
6-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
Session 2 Study Staff
Session 1 Study Staff mHealth Orientation
Study Staff
Outreach/In-Reach
Eligibility screen in community/
clinics
Baseline Visit
Survey, Biological*, Referral to
HD for HIV/STI Testing
Outreach/In-Reach
Eligibility screen in community/
clinics
Baseline Visit
Survey, Biological*, Referral to
HD for HIV/STI Testing
12-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
6-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
12-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
6-Month Follow-up
Survey, Biological*, Referral to
HD for HIV/STI Testing
SEEK
TEST
TREAT
AOD Abuse
RETAIN
AOD Abstain
YWC Face-to-Face
Sessions
Study Staff
YWC mHealth
Mobile Device
Fig. 1 Study design
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follow-up visits.
Study activities by arm
The study comprises three arms, described below. En-
rolled participants receive one of the three arms based
on the county in which they reside and the cycle in
which they enroll.
1. HCT (control) arm: Participants in counties
assigned to this control arm receive standard HCT
and STI testing services from the health department.
2. Intervention arms: Participants in counties
randomized to the intervention arms complete
either the face-to-face YWC or the mHealth YWC,
depending on their county assignment at the time
of enrollment. The YWC is an age-appropriate,
woman-focused intervention that seeks to reduce
sexual risk behaviors, reduce AOD use, and develop
female empowerment in young African American
women. The intervention involves two sessions that
include developing personalized action plans andproviding participants with condoms and lubricant to
practice skills learned during the intervention. The
first session of the intervention addresses alcohol,
drugs, sexual risks, and relationships, and the second
session addresses HIV and condom use, GBV, and
conflict resolution. This session also includes a
demonstration and rehearsal of both male and female
condoms. Throughout the intervention, videos of
African American women sharing their stories about
these topics are shown. At the end of each session,
participants work on personalized action plans to
create realistic and achievable risk-reduction and life
goals and steps to work toward these goals.
 Face-to-face YWC: Participants in the face-to-face
arm are asked to return to the health department, or
another public location with privacy that is convenient,
approximately 1 week after their intake appointment
for the first of the two individual intervention sessions
with a trained interventionist. The two intervention
sessions are targeted to be held 1 week apart.
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are asked to return to the health department, or
another public location that is convenient,
approximately 1 week after their intake appointment
for a brief appointment to pick up their designated
Android tablet with preloaded YWC application,
and to participate in an introduction to the
intervention with a staff member. The staff member
shows them how to operate the tablet and navigate
the app. Participants create a personal identification
number (PIN) for accessing the app, and perform a
test upload with the device to ensure that it can
connect to Wi-Fi and transmit their encrypted data,
to allow for monitoring of their progress. Wi-Fi is
not required to use the app, but participants are asked
to upload their data periodically, and an upload button
in the main menu of the app serves as a reminder.
Participants are given the same risk-reduction kit that
face-to-face participants are given, which includes
male and female condoms and lubricant, as the app
contains video demonstrations of how to use them.
Participants are also asked to practice during these
demonstrations. Participants then take the tablet
home to begin the intervention. The mHealth YWC
was designed to mirror this in-person delivery via a
self-guided mHealth application on a mobile device
that allows participants to cover the material at their
own pace. The mHealth YWC was developed on the
Personal Health Intervention Tool (PHIT) platform
[35], which is a generalized toolkit for implementing
mHealth applications. Data are stored locally on the
mobile device using an encrypted database to await
upload to a secure server, where they are available via
a password-protected website dashboard. These data
are monitored. Participants are asked to return their
tablet at their 6-month follow-up appointment.
Retention
To assist in participant retention for follow-up appoint-
ments, in addition to sessions (if applicable), detailed
contact information is collected from participants during
their intake appointment. This information includes
their address, phone number, social media account(s),
places they frequent, locations they would go if they
found themselves without a place to stay, whether they
give staff permission to visit their address if they cannot
be reached, in addition to the contact information of
others who are close to them. This detailed information
allows for multiple methods of communication to reach
participants if their contact information changes.
Additionally, to help with participant retention at
sessions and follow-up appointments, staff provide
transportation or transportation reimbursement, and
childcare (if needed).Outcomes
The primary outcomes for this study are self-reported
frequency of condomless sex, sexual negotiation (mea-
sured by the ability to negotiate condom use and other
sexual behavior with a male partner) and substance use.
Substance use will also be measured biologically through
urine drug screening to assess recent drug use and
breathalyzer tests to assess recent alcohol use. Secondary
outcome measures include reduced violence and
victimization assessed through self-reported experiences
of emotional, physical, and sexual abuse. All primary
and secondary outcomes will be measured at baseline,
6-month follow-up, and 12-month follow-up.
Participant timeline
The first study participant was enrolled in January 2017.
Active recruitment is expected to continue until July
2019. We anticipate the duration of each study partici-
pant’s involvement to be up to 1 year from the date of
first enrollment. The number of contacts a participant is
expected to have depends on the study condition to
which they are assigned. For the HCT arm, participants
have three contacts: intake, 6-month, and 12-month
follow-up appointments. Participants in the mHealth
arm have one additional contact, an appointment where
they pick up their tablets that contain the intervention
and learn about the mHealth app (a total of four
contacts). Participants in the face-to-face arm have two
additional contacts in the form of two intervention
sessions (a total of five contacts).
Sample size and power
This randomized trial aims to enroll up to 700 young
women, with an expected enrollment of 600 based on
the power calculation for the study design. We used the
Stata command sampncti [36], which is based on the
equation developed by Chow, Shao, and Wang [37] to
calculate the detectable difference in primary outcomes
between participants in the control arm and participants
in the face-to-face YWC arm. We hypothesize that the
participants in the face-to-face YWC arm and partici-
pants in the mHealth YWC arm would not have statisti-
cally significant different primary outcomes at 6 months;
therefore, we calculated the detectable difference based
on the control and face-to-face YWC arms. Our param-
eters were based on a sample size that is feasible
given the study design (n = 600; 200 participants per
arm; an average of 67 participants per condition per
county), three counties per arm, intraclass correlation
(ICC) = 0.10, and alpha = 0.05, and a two-sided test.
All outcome estimates are based on the principal
investigator’s (PI’s) previous studies conducted with
key populations of young women who use substances
in North Carolina [31] and in South Africa [38].
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To successfully reach and recruit young African American
women who use AOD and who have not tested recently
for HIV, recruitment strategies such as traditional
street-based outreach and marketing efforts are being
used. These methods have been successful in other studies
with women who use substances in North Carolina
[27, 31, 39]. Project staff frequent hotspots—such as bus
stops, shopping malls/centers, public housing, and local
colleges and universities—and distribute recruitment
flyers and cards. These traditional approaches are supple-
mented with innovative recruitment strategies via digital
platforms, such as Facebook, Instagram, and Twitter, and
local radio advertisements. In addition, recruitment occurs
in each health department—this method of recruitment is
referred to as in-reach. With permission, marketing of the
study is conducted throughout the health department by
project staff. As a supplement to these forms of recruit-
ment, a peer consultant program, which allows for refer-
rals from both study participants and nonparticipants, was
implemented to assist in recruitment of potential study
participants.
Modifications to protocol
Several modifications to the study protocol have institu-
tional review board (IRB) approval. Table 1 presents
these study modifications. The first three modifications
were made prior to participant enrollment.
Data management
All study participants are assigned a unique alphanumeric
participant identifier to be recorded on all study-related
physical and electronic data sources. Completed data
forms are stored in locked file cabinets in rooms located
in restricted areas at each health department. Documents
that contain identifying information (e.g., name, address,
e-mails, phone numbers) are stored in a locked file cabinet
separate from study data without these identifiers. Data
forms without identifiers are entered and transmitted toTable 1 Modifications to protocol
Date
Approved
Modification
September
2016
Revised eligibility criterion; increased incentive amounts
October 2016 Addition of Certificate of Confidentiality
December
2016
Changed type of drug screening test used; addition of partic
June 2017 Revised eligibility criterion
August 2017 Addition of peer consultant program to assist in recruitment
December
2017
Changed study design from a three-arm parallel group desig
instrument and updated consents to reflect change
January 2018 Changed distressed respondents’ protocol about who to coRTI through Blaise®, a survey data collection and manage-
ment system that has programmed data checks; data with
identifiers are not entered into Blaise. To ensure the qual-
ity of data, staff members are required to review each
other’s work. In addition, the project director, study co-
ordinator, and quality assurance coordinator periodically
visit each study site to perform quality checks. Hard-copy
data forms are destroyed 7 years after study completion.
Data analysis
Descriptives, including measures of central tendency
(e.g., mean, median), will be used to illustrate the varying
characteristics of the study population. The main effect
for the primary outcomes will be assessed by analyzing
each condition’s change over time between baseline and
each follow-up. Differences in rates of change between
conditions will be assessed by comparing the slopes
from the previous analysis.
Missing data
Although attempts will be made to minimize missing data,
we anticipate that some data will be missing despite these
efforts because of participant attrition and non-response.
We will explore patterns of missing data to determine
whether the missingness is at random. We will consider
data that are Missing at Random (MAR) to be explained
by observed covariates. If we believe that missingness is
due to unobserved factors (MNAR—Missing Not at
Random), then we will use selection models to identify
variables to explain it, or pattern mixture modeling. We
will examine whether the results of sensitivity analyses are
similar with and without missing data adjustments.
Data monitoring
A Data and Safety Monitoring Board (DSMB) has been
convened to protect the safety of participants and ensure
the integrity of collected data. The DSMB meets biannu-
ally and is composed of three professionals with expertise
in adolescent health and medicine, bioethics and women’sipant stamp card; inclusion of risk-reduction materials for YWC arms
of potential participants for study participation
n to a three-arm crossover design; added referral prompts to survey
ntact
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respectively. This board is independent from the re-
searcher and the sponsoring institution for the study.
DSMB members discussed whether stopping rules were
necessary for this study and they determined that these
rules were not necessary.
Reporting of adverse events
Because this study presents minimal risk to study partici-
pants, study-related adverse events (AEs) or serious
adverse events (SAEs) are unlikely. In the rare event that
study-related AEs or SAEs occur, staff are directed to
immediately notify the project director and PI or designee
(a trained clinical psychologist) and submit SAE and
incident reports. The PI will report SAEs within 48 h to
the National Institute on Drug Abuse (NIDA), RTI’s
Office of Research Protection, and the DSMB chair,
with a follow-up report submitted within 72 h after
initial reporting. The PI will report SAEs to the NIDA
Project Officer within 48 h of the event by e-mail. A
written follow-up will be sent within 72 h of the event.
Additionally, AEs and SAEs will be reported to RTI’s
IRB and in reports to the DSMB.
Ethics and dissemination
The experimental phase of the study received approval
from the RTI Committee for the Protection of Human
Subjects in August 2016. In addition, research committees
of Wake County Human Services and the Durham County
Department of Public Health reviewed the study and all
related materials with each organization, granting full study
approval in November 2016. The Guilford County Depart-
ment of Public Health Director granted approval in lieu of
a formal review by a research committee. All site-based
project staff have to complete RTI’s basic human subjects
research training module upon hire and before initial
contact with any potential study participants. This training
will be repeated annually. Furthermore, all staff members
responsible for data collection have signed Staff Agreements
of Confidentiality to pledge that they will ensure confidenti-
ality of participants and study data. The study findings will
be disseminated through our established Community
Collaborative Board, program newsletter, journal articles,
conference presentations, websites, and targeted dissemin-
ation meetings.
Discussion
HIV among African American women remains dispro-
portionate compared with other racial/ethnic groups of
women, especially in the southern United States. It is
critical to engage young African American women in the
HIV care continuum. This randomized trial seeks to test
the efficacy of two formats of the YWC—one is an innova-
tive mHealth delivery and the other is face-to-facedelivery—relative to standard HCT. A woman-focused
intervention delivered via an mHealth app may be appro-
priate, especially when adapted for this 18- to 25-year-old
population. If this format is found to be efficacious, an
mHealth app may succeed in expanding the reach of the
HIV risk-reduction intervention, making the YWC more
accessible to young women who use mobile devices.
Trial status
Enrolling.
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